Using apixaban (Eliquis; Bristol-Myers Squibb) for the treatment of atrial fibrillation (AF) is associated with significantly less gastrointestinal bleeding when compared with other direct oral ...
LAS VEGAS, NV—The first day of VIVA 2017 began with some timely insights into pharmacotherapy with non-vitamin K oral anticoagulants (NOACs) in patients with deep vein thrombosis (DVT), and a look ...
Please provide your email address to receive an email when new articles are posted on . Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding ...
For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban. Data remain inconclusive regarding ...
At both 6 months and 12 months follow-up, the rivaroxaban group was found to have more of these events than the apixaban group. Credit: Getty Images. In patients with atrial fibrillation and valvular ...
With the recent approval of apixaban in most major countries for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF), all 3 of the new oral ...
According to a new study, among patients receiving extended anticoagulation with apixaban for cancer-associated VTE, four ...
ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One ...
In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, ...
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of apixaban for the prevention of venous thromboembolism after elective total hip or knee replacement surgery ...
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Apixaban is recommended as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with non-valvular atrial fibrillation with 1 or more risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback